Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.67 Average Price Target from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX) has earned an average rating of “Moderate Buy” from the seven research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $8.6667.

A number of research firms have recently commented on GANX. Roth Mkm restated a “buy” rating and set a $10.00 price objective on shares of Gain Therapeutics in a research note on Friday, December 19th. Maxim Group lifted their target price on Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Friday, December 19th. BTIG Research reaffirmed a “buy” rating and set a $9.00 price target on shares of Gain Therapeutics in a research report on Wednesday, October 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Monday, December 29th.

Institutional Trading of Gain Therapeutics

Large investors have recently added to or reduced their stakes in the company. Apollon Wealth Management LLC acquired a new position in shares of Gain Therapeutics during the 4th quarter worth approximately $64,000. Oliver Luxxe Assets LLC bought a new position in Gain Therapeutics during the fourth quarter worth $65,000. JPMorgan Chase & Co. acquired a new position in shares of Gain Therapeutics in the third quarter valued at $47,000. Virtu Financial LLC raised its position in shares of Gain Therapeutics by 126.9% in the third quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock valued at $96,000 after purchasing an additional 30,207 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in shares of Gain Therapeutics during the 3rd quarter worth about $68,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Price Performance

NASDAQ GANX opened at $1.92 on Tuesday. The firm’s 50 day moving average is $2.90 and its 200-day moving average is $2.23. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $73.84 million, a PE ratio of -3.15 and a beta of 0.06. Gain Therapeutics has a 12-month low of $1.41 and a 12-month high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). Equities research analysts anticipate that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.